当前位置：
X-MOL 学术
›
J. Natl. Cancer Inst.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer.
Journal of the National Cancer Institute ( IF 10.3 ) Pub Date : 2019-04-16 , DOI: 10.1093/jnci/djz051 Utpal K Mukhopadhyay , Chetan C Oturkar , Christina Adams , Nadi Wickramasekera , Sanjay Bansal , Rajesh Medisetty , Austin Miller , Wendy M Swetzig , Laxmi Silwal-Pandit , Anne-Lise Børresen-Dale , Chad J Creighton , Jun Hyoung Park , Santhi D Konduri , Alka Mukhopadhyay , Alexander Caradori , Angela Omilian , Wiam Bshara , Benny Abraham Kaipparettu , Gokul M Das
Journal of the National Cancer Institute ( IF 10.3 ) Pub Date : 2019-04-16 , DOI: 10.1093/jnci/djz051 Utpal K Mukhopadhyay , Chetan C Oturkar , Christina Adams , Nadi Wickramasekera , Sanjay Bansal , Rajesh Medisetty , Austin Miller , Wendy M Swetzig , Laxmi Silwal-Pandit , Anne-Lise Børresen-Dale , Chad J Creighton , Jun Hyoung Park , Santhi D Konduri , Alka Mukhopadhyay , Alexander Caradori , Angela Omilian , Wiam Bshara , Benny Abraham Kaipparettu , Gokul M Das
Anti-tumorigenic vs pro-tumorigenic roles of estrogen receptor-beta (ESR2) in breast cancer remain unsettled. We investigated the potential of TP53 status to be a determinant of the bi-faceted role of ESR2 and associated therapeutic implications for triple negative breast cancer (TNBC).
中文翻译：
TP53 状态作为雌激素受体-β 在乳腺癌中促瘤与抗瘤作用的决定因素。
雌激素受体-β (ESR2) 在乳腺癌中的抗肿瘤发生与促肿瘤发生作用仍未确定。我们调查了 TP53 状态作为 ESR2 双面作用决定因素的潜力以及对三阴性乳腺癌 (TNBC) 的相关治疗意义。
更新日期：2019-04-16
中文翻译：
TP53 状态作为雌激素受体-β 在乳腺癌中促瘤与抗瘤作用的决定因素。
雌激素受体-β (ESR2) 在乳腺癌中的抗肿瘤发生与促肿瘤发生作用仍未确定。我们调查了 TP53 状态作为 ESR2 双面作用决定因素的潜力以及对三阴性乳腺癌 (TNBC) 的相关治疗意义。
京公网安备 11010802027423号